AstraZeneca’s presence in China boosted by Lynparza approval for ovarian cancer
Analysts said the prevalence of the BRCA-mutated ovarian cancer is higher in China and the approval will boost AstraZeneca’s already strong performance in the region
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 7 of 11
Addition by subtraction: AstraZeneca continues to slim down
It is selling the North American rights to its anti-psychotic products Seroquel and Seroquel XR. This is part of the Anglo-Swedish giant's focus on its core R&D portfolio and bunch blockbusters it owns
AstraZeneca cancer drug fast-tracked by the FDA
AZ wants to offer Imfinzi to people with late-stage small cell lung cancer
AstraZeneca's near-£100bn valuation is a vindication for Pascal Soriot
Since the Frenchman took the helm in October 2012, the drug giant's share price has increased by over 160%
AstraZeneca’s type-2 diabetes drug gets EU approval
Qtrilment, already approved in the US, comes in tablets and helps adults to control the level of sugar in the blood
AstraZeneca gets priority review in US for new NF1 treatment
The application is for the use of selumetinib in children aged three years and older.
AstraZeneca and the art of resurrecting failed drug candidates
Mereo and Evgen's drugs both stumbled as phase 2 trials yielded disappointing results, but an AstraZeneca-style turnaround could be around the corner
AstraZeneca’s lupus drug makes up for last year’s failure, faces competition
The FTSE 100-listed company said 47.8% of patients in phase III achieved a reduction of symptoms compared to 31.5% of those who used placebo
AstraZeneca anaemia drug data points to “yet another blockbuster”
Roxadustat could generate US$5bn in annual revenues, according to Shore Capital analysts
AstraZeneca to release data likely to move anaemia drug’s sales value by US$3.7bn, analysts say
Consensus is at US$1.3bn, although Shore Capital sees potential for up to US$5bn revenues if the US authorities do not deem necessary to include heart condition risks on the drug’s label
AstraZeneca to add $13bn product sales in next 5 years, says broker Liberum
Patent expiries have slowed Astra’s sales over the last few years, which retreated to $21bn in 2017, down from a peak of $34bn six years earlier
AstraZeneca hikes sales target after new drug successes
Product sales grew 16% in the third quarter, up from 12% in the first half of the year
Archive
FTSE 100 closes higher, bolstered by Aveva and AstraZeneca; Boris Johnson to seek December general election
The blue-chip benchmark finished ahead by 67.51 points at 7,328.25 on the day
AstraZeneca likely to remain in favour, banks update on PPI
Prudential completes its M&G demerger on Monday, with the week also seeing WPP and Travis Perkins follow recent profit warnings from rivals and Reckitt Benckiser's new CEO makes his debut
FDA grants “priority review” status to AstraZeneca’s breast cancer antibody
“Trastuzumab deruxtecan has the potential to transform the treatment landscape for patients with HER2-positive metastatic breast cancer"
AstraZeneca gets US clearance for asthma pen
Fasenra sales surged 244% in its latest quarter to US$296mln as it became the preferred novel-biologic medicine for the treatment of severe asthma.
IPO Roundup: Several biotech companies set to go public this week; WeWork cancels its IPO filing
ADC Therapeutics, a Swiss biotech, expects to lead the pack with a $200 million offering
Glaxo and AstraZeneca vie for position with "unprecedented" ovarian cancer trials
Both pharma companies' PARP inhibitor drugs reduced disease progression and death by up to 40% in clinical trials
AstraZeneca shares hit all-time highs as it adds colour to recent trial data
Top-line data earlier this year only revealed that the drugs in those studies achieved “statistically significant” results, but Astra has now been able to quantify their effects
AstraZeneca scores another late-stage win, this time with COPD drug
Breztri Aerosphere, even when taken in smaller doses, was shown to be much more effective in reducing the number of exacerbations suffered by COPD patients than current drugs
Amryt Pharma: The AIM drug developer potentially sitting on a US$100mln piece of paper
Amryt has a chance of being awarded a priority review voucher, which sell for several times more than the company’s current market cap
AstraZeneca scores another regulatory win in China for roxadustat anaemia drug
Astra will now be able to treat all Chinese patients living with chronic kidney disease who experience anaemia, regardless of whether they require dialysis
AstraZeneca’s cancer drug combo stumbles in phase III lung cancer trial
Astra had been hoping to show that the combination of Imfinzi and tremelimumab was more effective in treating certain lung cancer patients than chemo
AstraZeneca nears £100bn market cap as remarkable drug pipeline turnaround continues
Only five years ago, AstraZeneca’s Symbicort inhaler generated more sales than all of the firm’s cancer drugs combined. The same can’t be said any more…
AstraZeneca pumps higher as Farxiga shows benefit in late-stage heart-failure study
Farxiga, when combined with current standard of care, was able to reduce the risk of cardiovascular death and the worsening of heart failure
AstraZeneca’s Lynparza meets primary endpoint in late-stage ovarian cancer trial
AstraZeneca is competing with GSK to win the race to become the go-to maintenance treatment for people who have been treated for ovarian cancer
AstraZeneca’s market value swells by £4bn after forecast-busting second-quarter results
Revenue beat forecasts by 5%, while operating profit was particularly impressive, coming in some 17% ahead of expectations
Archive
FTSE 100 closes in red Thursday as ECB update underwhelms
There were mixed messages in Mario Draghi's update on Thursday
Archive
Day ahead preview: Unilever, National Express, Diageo, ECB
With a slew of corporate earnings and the European Central Bank's policy decision, Thursday will be a busy day of news
GSK names former AstraZeneca finance boss as new chairman
Jonathan Symonds will be the man tasked with overseeing the mega merger of GSK and Pfizer’s consumer healthcare businesses
Archive
ITV investors hope for Love Island boost amid tough ad market
The week ahead includes updates from ITV, Unilever, Rightmove, Diageo, Marston's, IG Group, National Express, GSK and AstraZeneca
GlaxoSmithKline edges higher as Zejula passes late-stage ovarian cancer study with flying colours
Zejula demonstrated a “statistically significant” improvement in progression free survival – the length of time a patient lives with the disease but it doesn’t get worse
US regulators grant orphan drug status to AstraZeneca’s Imfinzi cancer drug
Imfinzi recently showed in a late-stage study that, when combined with chemotherapy, it had a “clinically meaningful” effect on overall survival
AstraZeneca gets two positive opinions from European Medicines Agency committee
The Committee for Medicinal Products for Human Use (CHMP) recommended that diabetes medicine Forxiga should have its marketing authorisation updated to include cardiovascular data from recent clinical trials
AstraZeneca gets EU approval for Lynparza as ovarian cancer treatment
Pharma giant had been targeting annual peak sales of $2bn for the drug, of which $400mln was from ovarian cancer
AstraZeneca sees further encouraging effects from leukaemia treatment Calquence
Interim analysis of a phase III clinical trial has revealed that after 12 months, 88% of people saw no progression of the disease if they were given the drug
AstraZeneca drug for chronic lymphocytic leukaemia successfully navigates phase III trial
The results will “serve as the foundation for regulatory submissions later this year", said AZ’s vice president of oncology, José Baselga
AstraZeneca reports positive results from trial of pancreatic cancer treatment
Results from the trial of Lynparza showed “statistically significant and clinically meaningful improvement” in the time patients could live without their disease getting worse
Immuno-oncology: All you wanted to know but were too afraid to ask
Essentially, immuno-oncology involves developing drugs that use the body’s own immune system to fight cancers
Archive
Is London's fickle funding appetite part of Lasker's 'disastrous' cycle?
Stock market sage Bernard Lasker once said: “I can feel it coming...A whole new round of disastrous speculation, with all the familiar stages in order: blue-chip boom, then a fad for secondary issues, then an over-the-counter play, then a g
BHP, AstraZeneca and Shell among world’s top divi payers as shareholders gear up for record year of returns
Asset Manager Janus Henderson is predicting that global dividend pay-outs will reach almost US$1.5trn in 2019
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
AstraZeneca gets US regulatory green light for slow-release diabetes drug
Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control
Archive
Loungers sees good start to first day of trading on AIM
A look at some of the biggest risers and fallers in London on Monday
AstraZeneca first-quarter profits double as product sales revival continues but cash still a worry
The oncology portfolio has helped to turn around Astra’s product sales, which for years had been falling as key drugs went off-patent
Investments and investor services
FTSE 100 closes just in red as crude price decline hits resource stocks
The UK blue-chip index finished down nearly six points at 7,428 on Friday
Archive
City set for unusually busy Friday with RBS leading the way
Alongside RBS, AstraZeneca, Just Eat, WPP and Pearson are all due to publish first-quarter trading updates on Friday
Investments and investor services
FTSE 100 closes at near seven month high as no news is deemed good news
The UK blue-chip index finished up around 63 points at 7,523
While UK dividends hit record £19.7bn in first quarter, some FTSE 100 companies could be headed for cuts
Basic measures like dividend cover suggest a number of blue chips might be struggling to maintain their payouts at current levels
Archive
Once Easter is over, a plethora of blue-chip big guns are set to report trading updates and results
The Week Ahead will bring updates from the likes of Royal Bank of Scotland and Barclays, plus drugs giant AstraZeneca, and media groups WPP, Pearson and WPP
AstraZeneca’s new Japanese cancer drug tipped to rack up billions in annual sales
Liberum thinks trastuzumab deruxtecan can generate peak sales of more than US$3bn, given the drug’s potential in a host of cancer indications
AstraZeneca is still not converting top-line momentum into cash-flow, says UBS
Astra has affected a “momentous turnaround” in sales growth, but it has struggled to turn that top-line momentum into cash flow, according to UBS
AstraZeneca granted Breakthrough Therapy Designation for rare genetic condition treatment
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious condition and have shown promise in early-stage clinical trials
Circassia gets a double shot in the arm from US regulators
Two of its COPD drugs, Tudorza and Duaklir, have been given the thumbs-up from US regulators
AstraZeneca launches UK's biggest cash call this year to fund £5.2bn Japanese cancer deal
The £2.7bn share placing will be used to make an upfront payment to Daiichi Sankyo, which has developed a potentially breakthrough new treatment for breast cancer
Investments and investor services
FTSE 100 closes in positive territory as MPs vote down May's deal again
Footsie closed at 7,279, up nearly 45 points on the day
AstraZeneca wins regulatory approval for Europe's first type-1 diabetes drug taken by mouth
“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism
Investments and investor services
FTSE 100 closes higher as Bercow deals blow to May's Brexit plan
Bercow says the government can only bring back the vote if there has been substantial 'change' to the Brexit deal
FTSE 100 closes lower as Chinese data dents sentiment
The UK's premier share index closed down around 32 points at 7,074
Archive
IAG, Rolls Royce and British American Tobacco on the agenda for busy blue chip Thursday
Its set to be a busy day for blue-chip news in London on Thursday.
AstraZeneca reports pancreatic cancer trial success for Lynparza
Lynparza though showed significantly increased rates of survival in the phase III POLO trial
AstraZeneca rises as Brilinta medicine meets goal in Phase III clinical trial
The company said during the trial Brilinta, when taken in conjunction with aspirin, had shown “a statistically-significant reduction” in major adverse cardiovascular events, such as heart attacks or strokes, compared to taking aspirin alone
Archive
Hotchpotch of blue-chip results set to flow in coming week from likes of Rolls-Royce, ITV, WPP
The Week Ahead will also bring a trading update from AB Foods, plus final results from Standard Chartered, IAG, Persimmon, Rightmove, as well as the latest US GDP data
AstraZeneca posts first rise in annual product sales for almost ten years
Patent expiries on key blockbusters such as Crestor and Seroquel have put a huge dent in sales over the past decade or so, but Astra returned to growth in 2018
Archive
FTSE 100 closes a tad higher but sentiment dented by US data
FTSE 100 closed up just over six points at 7,197, while FTSE 250 shed over 74 at 18,898
Archive
Drug firms AstraZeneca and Indivior to be in spotlight on Thursday
AstraZeneca, Indivior and Coca-Cola HBC are among the higher profile names in the schedule for Thursday.
Archive
FTSE 100 closes higher as investors buoyed by trade talk optimism
The UK's premier share index added almost 58 points at 7,129, while the FTSE 250 also gained ground
Archive
Blue-chip corporate update mill to continue to grind, with RBS and AstraZenca to the fore
Aside from all the company news, the Week Ahead also brings the latest UK inflation and GDP growth data for investors to digest, while the Brexit saga will continue to roll on
Double boost from European and US regulators for AstraZeneca’s lung infection treatment
MEDI8897 is being developed as a treatment for a respiratory syncytial virus – a major cause of lower respiratory tract infection which affects around 90% of children under two
Lloyds added to JPMorgan Cazenove’s European Best Equity Ideas Overweight List
JPMorgan's European Best Equity Ideas list summarises the bank’s EMEA Equity research team’s views and top picks, covering both strategy and sector contributions
AstraZeneca appoints leading cancer researcher José Baselga as new head of oncology R&D
Baselga resigned from his position as physician-in-chief at Memorial Sloan Kettering Cancer Center last year amid reports that he had failed to disclose payments from healthcare companies in some of his research articles
Biotech CEOs gather in San Francisco to mull 2019 outlook
On the agenda at this year's Biotech Showcase is a panel discussion entitled “Cell and gene therapy: The financing surge” featuring Orgenesis CEO Vered Caplan
Investments and investor services
FTSE 100: The good, the BATS and the Ocado in 2018
For Ocado, it was a case of "eat my shorts" as short sellers got burnt while for BATS, not enough cigarettes got burnt as e-cigarettes rose in popularity
Hat-trick for AstraZeneca as its cancer and anaemia drugs come up trumps in three late-stage trials
Lynparza improved response rates in a subset of ovarian cancer patients, while Roxadustat boosted haemoglobin count in people with anaemia
GlaxoSmithKline shares drift lower as Morgan Stanley reinitiates coverage with ‘underweight’ stance
The US investment bank set a price target of 1,460p on the FTSE 100-listed firm, with Glaxo's shares trading at 1,476.20p late morning, down 0.4% on Thursday’s closing price
Sterling slump: Who’s benefitting?
On Monday, fresh Brexit volatility pushed the pound to a yearly low against the dollar but despite the turmoil, some firms are profiting handsomely
AstraZeneca’s Imfinzi cancer drug fails in another late-stage trial
The drug failed to prolong the lives of patients with advanced head and neck cancers when it was used alone or in combination with another treatment, in comparison to standard chemo
Barclays downgrades GSK; warns of “significant EPS dilution” from Tesaro acquisition
Barclays reckons the GSK valuation remains appealing, but is waiting until 2019 before piling back in, as it thinks the shares might drift a little lower yet
AstraZeneca in cancer drug setback
The phase III trial involved patients with very late stage lung cancer where the disease had spread to other organs - in other words, the group was hard to treat
Investments and investor services
FTSE 100 closes Friday in the red after tumultuous week for UK politics
The UK's premier share index lost around 24 points at 7,013 on the day - and was down 1.29% on the week.
AstraZeneca sells off US rights to children’s lung disease treatment for up to US$2bn
Over the past couple of weeks, the FTSE 100 drugs giant has sold off the rights to three asthma and hay fever treatments, one heartburn medicine, an arthritis drug and now a lung disease treatment
AstraZeneca serves up a double dose of good news
It said the US regulator had granted a priority review for its new cancer treatment and told investors a phase III trial of its diabetes medication delivered impressive results
Growing opportunities in respiratory space could accelerate Circassia’s path to profitability, says analyst
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
AstraZeneca confirms full-year guidance; CEO says results mark an important milestone
Total revenues were still stuck in reverse gear, but the underlying picture, measured by product sales, was healthier with the figure up 8% to US$5.27bn
Investments and investor services
FTSE 100 closes higher ahead of Federal Reserve meeting
The focus is now on the Federal Reserve meeting later. The interest rate announcement is set for 7.00pm, UK time
Investments and investor services
J Sainsbury and retailers to be among highlights amid busy Thursday schedule
Sainsbury, Superdry and Burberry are among the names in the diary for Thursday.
AstraZeneca sells off three more non-core drugs for US$370mln
The UK drugs giant has been selling off lots of ‘non-core’ drugs in recent years to help keep money flowing in while it spends millions developing its pipeline
N4 Pharma surges as MedImmune agrees to extend collaboration deal
The two parties had been working together as part of a project funded by the UK government and they have agreed to continue their research
Archive
Trump mid-term test and US rate decision to give week ahead a Trans-Atlantic twist
Aside from the US elections and Fed policy meeting, updates from UK blue-chip retailers J Sainsbury, Wm Morrison Supermarkets and Marks & Spencer should draw the most attention in the coming week
Concepta readies for imminent UK launch of myLotus in first milestone of European strategy
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
AstraZeneca sells rights to two of its ‘non-core’ drugs for almost US$1bn
Both Nexium, a treatment for heartburn, and Vimovo, used to treat arthritis, fall outside of AstraZeneca’s three main focus areas of cancer, cardiovascular and renal and respiratory
AstraZeneca reveals trial of Lynparza drug reduces risk of ovarian cancer worsening
Deutsche Bank said the successful trial of Lynparza further increases its ‘buy’ conviction and raised its target price to 6,500p from 6,400p
AstraZeneca’s Lynparza given orphan drug status for treatment of pancreatic cancer
Orphan drug status gives drugmakers certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive
Redx Pharma to focus on progressing oncology and fibrotic drugs in 2019
2019 will be an important year for the firm with the re-start of Phase I/IIa trial for RXC004, part of a niche, and potentially breakthrough group of cancer drugs
Arix Bioscience teams up with Takeda to invest in cancer drug developer VelosBio
Arix is investing US$11mln in VelosBio through a Series A funding round in return for an 11.2% stake in the company
Archive
Proactive news snapshot: Sirius Minerals, Clinigen,, Erris Resources, Midatech Pharma...
A glance at some of the day's highlights from the Proactive Investors newswire
AstraZeneca collaboration helps Circassia narrow losses significantly in first half
Circassia promotes AstraZeneca’s Tudorza COPD drug in the US in return for a share of the profits, while it also has the commercial rights to another COPD drug made by AstraZeneca called Duaklir
FTSE 100 closes in positive territory as US dollar builds on gains
The pound is off 0.52% against the greenback at the time of writing..
AstraZeneca drug successfully negotiates final-stage clinical trial
A total of 17,000 people with type-2 diabetes took part in the study
AstraZeneca leukaemia drug receives US regulatory green light
In clinical trials, 75% of the people taking the drug responded to it. In 30% of cases, Lumoxiti had a “complete durable” effect